$BRKR

Munch Mark sold $110K of BRKR

Munch Mark (EXEC VP&PRES BRUKER NANO INC.) sold 2,000 shares of BRUKER CORP (BRKR) at $54.76 ($0.11M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Munch Mark
Published Jun 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
high confidence
Mentioned
$BRKR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

This is a primary-source disclosure of an insider sale, but the presence of a pre-arranged 10b5-1 plan typically makes it lower-signal for fundamentals.

02

Market read

Traders may note the disclosed sale size and timing, but it is unlikely to drive a material repricing absent other company-specific news.

03

What to watch

The article does not disclose motivations, remaining plan schedule, or whether other insiders sold around the same time, limiting inference.

Relevance 3/10Novelty 2/10Timing: SEC Form 4 filed 2026-06-16, covering a sale executed 2026-06-15.

Background

The filing is an SEC Form 4 insider transaction for Bruker Corp, reported by an executive officer and executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$BRKRNeutralHigh confidence
Context

Form 4 shows Bruker insider Munch Mark sold 2,000 shares at $54.76 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is typically absorbed as non-informational 10b5-1 selling.

Evidence & confidence

The transaction is explicitly coded as an open-market sale and states a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive value versus discretionary sales.

Market effects

No sector-level implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation or liquidity management, so traders may still watch for follow-on selling patterns.

Key entities

  • BRUKER CORP

    Subject of the Form 4 insider transaction disclosure.

  • Munch Mark

    Executive VP and President of Bruker Nano Inc., reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

J.P. Morgan Downgrades Bruker Corporation (BRKR) to Neutral Amid

J.P. Morgan downgraded Bruker Corporation (BRKR) to Neutral with a $70 price target, citing concerns about its Academia & Government segment and uncertain revenue growth. Bruker's P/S ratio is 2.45x, below its historical median and industry average. The company has a GF Score of 84/100, with strengths in valuation and momentum, but faces insider selling and mixed institutional interest.

$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.